Related Experiment Video
Updated: May 14, 2026
10:43
Expression, Detergent Solubilization, and Purification of a Membrane Transporter, the MexB Multidrug Resistance Protein
Published on: December 3, 2010
The anticancer agent prodigiosin is not a multidrug resistance protein substrate
Fatemeh Elahian1, Bahareh Moghimi, Farideh Dinmohammadi
1Department of Pharmaceutical Biotechnology, School of Pharmacy, Zanjan University of Medical Sciences, Zanjan, Iran.
DNA and Cell Biology
|February 5, 2013
Summary
Prodigiosin, a natural pigment from Serratia marcescens, shows potent anticancer activity. This compound effectively targets multidrug-resistant cancer cells, operating independently of common drug resistance transporters.
Area of Science:
- Microbiology
- Biochemistry
- Pharmacology
Background:
- Prodiginines are natural pigments with diverse biological activities, including anticancer properties.
- Multidrug resistance (MDR) in cancer limits the efficacy of chemotherapy.
- Understanding prodigiosin's interaction with MDR mechanisms is crucial for its therapeutic potential.
Purpose of the Study:
- To isolate and characterize prodigiosin from Serratia marcescens.
- To evaluate the cytotoxic effects of prodigiosin on multidrug-resistant cancer cell lines.
- To investigate the mechanism of prodigiosin action in relation to MDR transporters.
Main Methods:
- Isolation and identification of Serratia marcescens SER1 strain using 16s rDNA.
- Purification of prodigiosin via silica chromatography and structural analysis using (1)H-NMR spectroscopy.
- Assessment of cell cytotoxicity and drug accumulation/efflux using FACS analysis on MDR cell lines.
Main Results:
- Prodigiosin exhibited similar cytotoxic effects on both drug-resistant and parental cell lines.
- The compound's action was independent of MDR1, BCRP, and MRP2 transporter overexpression.
- FACS analysis confirmed prodigiosin accumulation and efflux are not mediated by these MDR transporters.
Conclusions:
- Prodigiosin is a promising anticancer agent effective against multidrug-resistant cancer cells.
- Its mechanism of action bypasses common MDR efflux pumps, suggesting a novel therapeutic strategy.
- Prodigiosin may serve as a potential treatment for cancers that overexpress multidrug resistance transporters.
Related Concept Videos
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:06Carrier-Mediated Transport
Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:30Prodrugs
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Prodrugs help overcome...